PATENTS related term(s) Copyrights

Amendments

Health: reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), H3873, H3874, H3876, H3877, H3878, H3879, H3880, H3882, H3883, H3884, H3885, H3886, H3887, H3888, H3889, H3891, H3892, H3893, H3894, H3896, H3897, H3898, H3900, H3901 [16MY]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), consideration (H. Res. 377), H3811 [15MY]

Bills and resolutions

Business and industry: provide that a patent owner may not assert sovereign immunity as a defense in certain actions before the Patent and Trademark Office (see S. 440), S1275 [12FE]

Copyrights: establish an alternative dispute resolution program for copyright small claims (see S. 1273), S2569 [1MY] (see H.R. 2426), H3403 [1MY]

Courts: include exclusive economic zone as part of U.S. for patent infringement (see H.R. 3954), H7377 [24JY]

——— subject entities on Dept. of Commerce banned Entity List to heightened pleading standards, additional transparency requirements, and other restrictions relative to sale or license of patents (see S. 2178), S4948 [18JY]

Dept. of Defense: develop guidelines and resources on acquisition or licensing of intellectual property (see H.R. 3313), H4770 [18JN]

Dept. of Homeland Security: authorize U.S. Customs and Border Protection to seize imported merchandise that infringes a design patent (see S. 2987), S6888 [5DE]

Double patenting: prevent (see H.R. 3199), H4431 [11JN]

Drugs: clarify and improve patent infringement litigation process for biological products to expedite getting generic drugs to market (see H.R. 3991), H7463 [25JY]

Economy: strengthen patent system and combat abuse (see S. 2082), S4773 [10JY] (see H.R. 3666), H5583 [10JY]

FDA: amend exclusivity period granted to a first generic drug application (see S. 3092), S7156 [18DE]

——— clarify types of patents on safe and effective drug list, require list of applicable exclusivities for listed drugs, update patent sponsor requirements, and reform patent list guidelines (see S. 1617), S3059 [22MY] (see H.R. 1503), H2366 [5MR]

——— codify policy of requiring drug products to contain an active moiety that has not been used in a previously approved product in granting new chemical entity exclusivity (see S. 1636), S3104 [23MY]

——— ensure valid generic drugs may enter the market by removing generic drug exclusivity period from any generic company that enters into pay-for-delay settlements with brand-name drug manufacturers (see H.R. 1506), H2366 [5MR]

——— increase competition in generic drug market by removing barriers for a generic drug to come to market by curbing patent manipulation by brand name drug manufacturers (see S. 1209), S2435 [11AP] (see H.R. 3812), H5999 [17JY]

——— prevent inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and provide incentives for drug innovation (see S. 344), S919 [6FE] (see H.R. 990), H1389 [6FE]

——— require manufacturers of approved biological products to disclose and list patents, biosimilarity, and exclusivity information relative to their products and promote biosimilar competition (see S. 659), S1659 [5MR] (see H.R. 4850), H8457 [23OC]

——— shorten exclusivity period for brand name biological products (see H.R. 3379), H5005 [20JN]

FTC: prohibit anticompetitive use of patents by drug product manufacturers (see S. 1416), S2770 [9MY] (see H.R. 4398), H7834 [19SE] (see H.R. 5133), H8958 [18NO]

——— provide that certain bad faith communications in connection with assertion of a patent are unfair or deceptive acts or practices (see H.R. 108), H205 [3JA]

Health: reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), consideration (see H. Res. 377), H3787 [14MY]

Intellectual property: remove requirement that certain covered entities prove they were irreparably harmed when seeking preliminary injunctions in civil actions for infringement and place conditions on export privileges (see H.R. 2841), H4009 [20MY]

Inventors: restore patent rights (see H.R. 5478), H12210 [18DE]

National Academy of Inventors: grant Federal charter (see H.R. 2857), H4063 [21MY]

Patent and Trademark Office: allow acceleration certificates awarded under the Patents for Humanity Program to be transferable (see S. 2814), S6475 [7NO]

——— require voluntary collection of demographic information for patent applications (see S. 2281), S5107 [25JY] (see H.R. 4075), H7467 [25JY]

Pharmaceuticals: prohibit biological product manufacurers from compensating biosimilar and interchangeable product companies to delay entry of biosimilar and interchangeable products into the market (see H.R. 1499), H2366 [5MR]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (see S. 64), S103 [9JA] (see H.R. 1344), H2100 [25FE] (see H.R. 1499), H2366 [5MR]

——— prohibit prescription drug manufacturers from compensating other companies to delay entry of generic drugs, biosimilar biological products, or interchangeable biological products into the market (see H.R. 2375), H3302 [29AP]

SBA: improve commercialization activities in Small Business Innovation Research Program and Small Business Technology Transfer Program (see S. 2127), S4856 [16JY] (see H.R. 3839), H7150 [18JY]

Letters

U.S.-Mexico-Canada Agreement (USMCA) provision relative to copyright legal remedies and safe harbors: Representatives Nadler and Collins, Committee on the Judiciary (House), H12258 [19DE]

Lists

National Academy of Inventors fellow inductees, E466 [15AP]

Motions

Health: reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), H3904 [16MY]

Notices

Estimated budget effects of H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, H3786 [14MY], H3921 [16MY]

Intention to object to S. 1273, Copyright Alternative in Small-Claims Enforcement (CASE) Act: Senator Wyden, S5668 [24SE]

Remarks in House

Copyrights: establish an alternative dispute resolution program for copyright small claims (H.R. 2426), H8345–H8353 [22OC]

FDA: clarify types of patents on safe and effective drug list, require list of applicable exclusivities for listed drugs, update patent sponsor requirements, and reform patent list guidelines (H.R. 1503), H3486–H3488 [8MY], H4401 [11JN]

Foreign trade: address violations of U.S. intellectual property rights, E1619 [19DE]

Health: reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), H3715 [10MY], H3731 [14MY], H3800 [15MY], H3851, H3852, H3853–H3911, H3913 [16MY], H4123 [23MY], H4401 [11JN], H5085 [25JN], H5175 [26JN], H7693 [12SE], H9248 [4DE], E623 [17MY]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), consideration (H. Res. 377), H3801–H3813 [15MY]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), corrections in engrossment, H3911 [16MY]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), motion to recommit, H3908, H3909 [16MY]

House of Representatives: legislative priorities, H2692 [13MR]

National Academy of Inventors: tribute to fellow inductees, E465 [15AP]

Pharmaceuticals: prohibit biological product manufacturers from compensating biosimilar and interchangeable product companies to delay entry of biosimilar and interchangeable products into the market, H3800 [15MY], H3856 [16MY]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, H3800 [15MY], H3856 [16MY]

——— prohibit prescription drug manufacturers from compensating other companies to delay entry of generic drugs, biosimilar biological products, or interchangeable biological products into the market (H.R. 2375), H3296 [29AP], H3455 [7MY]

Remarks in Senate

Business and industry: provide that a patent owner may not assert sovereign immunity as a defense in certain actions before the Patent and Trademark Office (S. 440), S4753 [10JY]

China: address violations of U.S. intellectual property rights, S878 [6FE], S1413 [25FE], S1499 [27FE], S1557 [28FE], S1610 [4MR], S1638 [5MR], S1720 [7MR], S1751 [11MR], S1782 [12MR], S1810 [13MR]

Committee on Homeland Security and Governmental Affairs (Senate): Permanent Subcommittee on Investigations release of ‘‘Threats to the U.S. Research Enterprise—China’s Talent Recruitment Plans’’ report, S6740 [21NO]

Copyrights: establish an alternative dispute resolution program for copyright small claims (S. 1273), S5668 [24SE]

FDA: increase competition in generic drug market by removing barriers for a generic drug to come to market by curbing patent manipulation by brand name drug manufacturers (S. 1209), S2854–S2856 [15MY]

——— require manufacturers of approved biological products to disclose and list patents, biosimilarity, and exclusivity information relative to their products and promote biosimilar competition, S5158 [30JY], S6527 [13NO]

——— require manufacturers of approved biological products to disclose and list patents, biosimilarity, and exclusivity information relative to their products and promote biosimilar competition (S. 659), S1752–S1754 [11MR], S2252 [4AP], S2872 [15MY]

FTC: prohibit anticompetitive use of patents by drug product manufacturers (S. 1416), S2870 [15MY], S3180 [4JN], S4488 [25JN], S4762, S4763 [10JY], S5009 [23JY], S5506 [17SE], S6217 [29OC], S6272 [30OC], S6368 [5NO], S6459 [7NO], S6497 [12NO], S6520–S6524, S6527 [13NO], S6640 [19NO], S6742 [21NO]

——— prohibit anticompetitive use of patents by drug product manufacturers (S. 1416), unanimous-consent request, S6521–S6523 [13NO], S6967, S6968 [11DE]

Health: reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), S6934 [10DE]

Patent and Trademark Office: require voluntary collection of demographic information for patent applications (S. 2281), S5110 [25JY]

Pharmaceuticals: prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (S. 64), S2001 [26MR], S6527 [13NO]

Schweitzer, Edmund O., III: National Inventors Hall of Fame inductee, S584 [24JA]

Reports filed

Affordable Prescriptions for Patients Act: Committee on the Judiciary (Senate) (S. 1416), S4676 [28JN]

Consideration of H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act: Committee on Rules (House) (H. Res. 377) (H. Rept. 116–61), H3787 [14MY]

Copyright Alternative in Small-Claims Enforcement (CASE) Act: Committee on the Judiciary (House) (H.R. 2426) (H. Rept. 116–252), H8386 [22OC]

——— Committee on the Judiciary (Senate) (S. 1273) (S. Rept. 116–105), S5474 [12SE]

Orange Book Transparency Act: Committee on Energy and Commerce (House) (H.R. 1503) (H. Rept. 116–47), H3438 [2MY]

Preserving Access to Cost Effective Drugs (PACED) Act: Committee on the Judiciary (Senate) (S. 440), S4676 [28JN]

Protecting Consumer Access to Generic Drugs Act: Committee on Energy and Commerce (House) (H.R. 1499) (H. Rept. 116–52), H3725 [10MY]

Tables

Estimated pay-as-you-go effects of H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, H3786 [14MY], H3921 [16MY]

Texts of

H. Res. 377, consideration of H.R. 5, Equality Act, H.R. 312, Mashpee Wampanoag Tribe Reservation Reaffirmation Act, and H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, H3801 [15MY]

H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, H3868–H3873 [16MY]

H.R. 1503, Orange Book Transparency Act, H3486 [8MY]

H.R. 2426, Copyright Alternative in Small-Claims Enforcement (CASE) Act, H8345–H8352 [22OC]